80 FR 66546 - Findings of Research Misconduct
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary Federal Register Volume 80, Issue 209 (October 29, 2015)
Office of the Secretary
Federal Register Volume 80, Issue 209 (October 29, 2015)
| Page Range | 66546-66546 | |
| FR Document | 2015-27587 |
[Federal Register Volume 80, Number 209 (Thursday, October 29, 2015)] [Notices] [Page 66546] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-27587] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct AGENCY: Office of the Secretary, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Dr. Maria C.P. Geraedts, University of Maryland, Baltimore: Based on the report of an investigation conducted by the University of Maryland, Baltimore (UMB) and analysis conducted by ORI in its oversight review, ORI and UMB found that Dr. Maria C.P. Geraedts, former postdoctoral fellow, Department of Anatomy and Neurobiology, UMB, engaged in research misconduct in research supported by National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), grant R01 DC010110. ORI found falsified and/or fabricated data included in the following two (2) publications:Am J Physiol Endocrinol Metab 303:E464-E474, 2012 (hereafter referred to as ``AJP 2012'') Journal of Neuroscience 33(17):7559-7564, 2013 (hereafter referred to as ``JN 2013'') As a result of the UMB investigation, JN 2013 and AJP 2012 have been retracted. ORI found that Respondent falsified and/or fabricated bar graphs in AJP 2012, by changing ELISA-based measurements to produce the desired result for secretion of glucagon-like peptide-1 (GLP-1) from intestinal explants from various mouse strains in: Figure 2 for GLP-1 release from duodenum (2A & D), jejunum (2B & E), and ileum (2C & F). Figure 3 for GLP-1 release from colon (3A & C) and rectum (3D). Figure 4 for GLP-1 release from ileum (4A) and colon (4C) in the presence or absence of an ATP-sensitive K+ channel inhibitor. ORI found that Respondent falsified and/or fabricated bar graphs in Figure 1, JN 2013 by changing ELISA-based measurements to produce the desired result for the secretion of peptides found in taste buds (GLP- 1, glucagon, or neuropeptide Y) from mouse lingual epithelium exposed to various concentrations of stimuli (glucose, sucralose, MSG, polycose). These bar graphs also were included as Figure 7 in grant application R01 DC010110-06. Both the Respondent and the U.S. Department of Health and Human Services (HHS) want to conclude this matter without further expenditure of time or other resources and have entered into a Voluntary Settlement Agreement (Agreement) to resolve this matter. Respondent stated that she is not currently involved in U.S. Public Health Service (PHS)- supported research and has no intention of applying for or engaging in PHS-supported research or otherwise working with PHS. Dr. Geraedts has entered into a Voluntary Settlement Agreement with ORI and UMB, in which she voluntarily agreed to the administrative actions set forth below. The administrative actions are required for three (3) years beginning on the date of Dr. Geraedts employment in a position in which she receives or applies for PHS support on or after the effective date of the Agreement (September 22, 2015). If the Respondent has not obtained employment in a research position in which she receives or applies for PHS support within one (1) year of the effective date of the Agreement, the administrative actions set forth below will no longer apply. Dr. Geraedts has voluntarily agreed: (1) To have her research supervised as described below and notify her employer(s)/institution(s) of the terms of this supervision; Respondent agreed that prior to the submission of an application for PHS support for a research project on which her participation is proposed and prior to her participation in any capacity on PHS- supported research, Respondent shall ensure that a plan for supervision of her duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of her research contribution; Respondent agreed that she will not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that any institution employing her shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for period of three (3) years beginning on September 22, 2015. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015-27587 Filed 10-28-15; 8:45 am] BILLING CODE 4150-31-P
![66546 Federal Register / Vol. 80, No. 209 / Thursday, October 29, 2015 / Notices
of Planning, Analysis, and Evaluation of Anatomy and Neurobiology, UMB, (September 22, 2015). If the Respondent
(RA5). Specifically, this notice: (1) engaged in research misconduct in has not obtained employment in a
Establishes the Office of Strategic research supported by National Institute research position in which she receives
Initiatives (RA59). on Deafness and Other Communication or applies for PHS support within one
Establish the functional statement for Disorders (NIDCD), National Institutes (1) year of the effective date of the
the Office of Strategic Initiatives (RA59) of Health (NIH), grant R01 DC010110. Agreement, the administrative actions
within the Office of Planning, Analysis, ORI found falsified and/or fabricated set forth below will no longer apply. Dr.
and Evaluation (RA5). data included in the following two (2) Geraedts has voluntarily agreed:
publications:
Office of Strategic Initiatives (RA59) • Am J Physiol Endocrinol Metab (1) To have her research supervised as
(1) Provides HRSA-wide leadership 303:E464–E474, 2012 (hereafter referred described below and notify her
on cross-agency initiatives and to as ‘‘AJP 2012’’) employer(s)/institution(s) of the terms of
departmental priorities; (2) maintains • Journal of Neuroscience this supervision; Respondent agreed
liaison between the Administrator, other 33(17):7559–7564, 2013 (hereafter that prior to the submission of an
OPDIVs, Office of the Secretary staff referred to as ‘‘JN 2013’’) application for PHS support for a
components, and other Departments on As a result of the UMB investigation, research project on which her
priority initiatives; (3) provides JN 2013 and AJP 2012 have been participation is proposed and prior to
technical assistance to Agency programs retracted. her participation in any capacity on
in order to help them respond to ORI found that Respondent falsified PHS-supported research, Respondent
emerging issues affecting the health care and/or fabricated bar graphs in AJP shall ensure that a plan for supervision
safety net; (4) coordinates outreach to 2012, by changing ELISA-based of her duties is submitted to ORI for
grantees and stakeholders on high measurements to produce the desired
approval; the supervision plan must be
profile public health initiatives; (5) result for secretion of glucagon-like
designed to ensure the scientific
establishes an infrastructure and peptide-1 (GLP–1) from intestinal
explants from various mouse strains in: integrity of her research contribution;
strategic direction of priority initiatives Respondent agreed that she will not
and institutionalizes these efforts into • Figure 2 for GLP–1 release from
duodenum (2A & D), jejunum (2B & E), participate in any PHS-supported
HRSA programs; and (6) coordinates the
and ileum (2C & F). research until such a supervision plan is
Agency’s long-term strategic planning
process. • Figure 3 for GLP–1 release from submitted to and approved by ORI;
colon (3A & C) and rectum (3D). Respondent agreed to maintain
Delegations of Authority • Figure 4 for GLP–1 release from responsibility for compliance with the
All delegations of authority and re- ileum (4A) and colon (4C) in the agreed upon supervision plan;
delegations of authority made to HRSA presence or absence of an ATP-sensitive (2) that any institution employing her
officials that were in effect immediately K+ channel inhibitor. shall submit in conjunction with each
prior to this reorganization, and that are ORI found that Respondent falsified
and/or fabricated bar graphs in Figure 1, application for PHS funds, or report,
consistent with this reorganization, manuscript, or abstract involving PHS-
shall continue in effect pending further JN 2013 by changing ELISA-based
measurements to produce the desired supported research in which
re-delegation. Respondent is involved, a certification
This reorganization is effective upon result for the secretion of peptides
found in taste buds (GLP–1, glucagon, or to ORI that the data provided by
date of signature. Respondent are based on actual
neuropeptide Y) from mouse lingual
Dated: October 18, 2015. epithelium exposed to various experiments or are otherwise
James Macrae, concentrations of stimuli (glucose, legitimately derived, and that the data,
Acting Administrator. sucralose, MSG, polycose). These bar procedures, and methodology are
[FR Doc. 2015–27592 Filed 10–28–15; 8:45 am] graphs also were included as Figure 7 in accurately reported in the application,
BILLING CODE 4165–15–P grant application R01 DC010110–06. report, manuscript, or abstract; and
Both the Respondent and the U.S. (3) to exclude herself voluntarily from
Department of Health and Human serving in any advisory capacity to PHS
DEPARTMENT OF HEALTH AND Services (HHS) want to conclude this
including, but not limited to, service on
HUMAN SERVICES matter without further expenditure of
any PHS advisory committee, board,
time or other resources and have
Office of the Secretary and/or peer review committee, or as a
entered into a Voluntary Settlement
Agreement (Agreement) to resolve this consultant for period of three (3) years
Findings of Research Misconduct matter. Respondent stated that she is not beginning on September 22, 2015.
AGENCY: Office of the Secretary, HHS. currently involved in U.S. Public Health FOR FURTHER INFORMATION CONTACT:
ACTION: Notice. Service (PHS)-supported research and Acting Director, Office of Research
has no intention of applying for or Integrity, 1101 Wootton Parkway, Suite
SUMMARY: Notice is hereby given that engaging in PHS-supported research or 750, Rockville, MD 20852, (240) 453–
the Office of Research Integrity (ORI) otherwise working with PHS. Dr. 8200.
has taken final action in the following Geraedts has entered into a Voluntary
case: Settlement Agreement with ORI and Donald Wright,
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Dr. Maria C.P. Geraedts, University of UMB, in which she voluntarily agreed Acting Director, Office of Research Integrity.
Maryland, Baltimore: Based on the to the administrative actions set forth [FR Doc. 2015–27587 Filed 10–28–15; 8:45 am]
report of an investigation conducted by below. The administrative actions are BILLING CODE 4150–31–P
the University of Maryland, Baltimore required for three (3) years beginning on
(UMB) and analysis conducted by ORI the date of Dr. Geraedts employment in
in its oversight review, ORI and UMB a position in which she receives or
found that Dr. Maria C.P. Geraedts, applies for PHS support on or after the
former postdoctoral fellow, Department effective date of the Agreement
VerDate Sep<11>2014 23:37 Oct 28, 2015 Jkt 238001 PO 00000 Frm 00059 Fmt 4703 Sfmt 9990 E:\FR\FM\29OCN1.SGM 29OCN1](https://thefederalregister.org/doc/80_FR_66755/page/1.svg)
Document Created: 2015-12-14 15:21:07
Document Modified: 2015-12-14 15:21:07
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. | |
| FR Citation | 80 FR 66546 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR